Lineage Cell Therapeutics Sells 12 Million Shares to Janus Henderson for $21 Million
Lineage Cell Therapeutics Inc. has sold 12 million common shares to Janus Henderson Investors for $21 million, at a price of $1.75 per share. This transaction was executed under its at-the-market offering program, generating gross proceeds before fees and expenses.
Lineage Cell Therapeutics Inc. announced the sale of 12 million common shares to Janus Henderson Investors at a price of $1.75 per share in a block transaction conducted under its at-the-market offering program. The transaction generated $21 million in gross proceeds for the company before fees and expenses. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-276249), on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
